Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

TG Therapeutics Inc

TGTX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$48.74

▲ +1.67%

Market Cap $7.46B · Vol 413.52K

Key Metrics

P/E Ratio

17.75

FWD: 22.23

Market Cap

$7.46B

Mid Cap

Div Yield

N/A

EPS Growth

-58.90%

YoY

RSI (14)

30.56

Momentum

Beta

1.63

vs Market

52W High

$59.30

17.81% below

52W Low

$26.76

82.14% above

Volume

413.52K

Avg 878.40K

P/B

7.14

Price-to-book

ROE

102.75%

Return on equity

Free Float

92.53%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, TG Therapeutics Inc (TGTX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TGTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.05%

-11.20%

+19.49%

+71.02%

YTD

+63.50%

+75.51%

+322.72%

+113.87%

Financials & Valuation

TTM · Annual

Total Revenue	$616.29M
Net Income	$447.18M
Revenue Growth (YoY)	+70.27%
Gross Margin	83.66%
Operating Margin	20.01%
Net Profit Margin	72.56%
ROE	102.75%
ROA · ROIC	13.09% · 81.37%

P/E Ratio	17.75
Forward P/E (FY1)	22.23
PEG Ratio	0.01
P/S	7.81
P/B	7.14
P/FCF	N/A
EPS Growth	-58.90%
Outstanding Shares	153.07M

Technical Indicators

50-Day SMA	$51.96
200-Day SMA	$37.40
RSI (14)	30.56
Beta	1.63
52-Week High	$59.30
52-Week Low	$26.76

Volume Today	413.52K
Avg Daily Volume (30D)	878.40K
Relative Volume	0.47x
Volatility (10D)	69.12
Volatility (30D)	52.86
Free Float	92.53%

Analyst Consensus

BUY

Current Price $48.74

Mean Target $69.33

52W Low$26.76 52W High$59.30

Current

Target

$26.76 $59.30

Current Analyst target

+42.25% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S8NH06

ISINUS88322Q1085

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.